Article Details

Survival Advantage Is Experienced by Patients Receiving Apalutamide Added to ADT for mCSPC

Retrieved on: 2021-02-13 16:52:30

Tags for this article:

Click the tags to see associated articles and topics

Survival Advantage Is Experienced by Patients Receiving Apalutamide Added to ADT for mCSPC. View article details on hiswai:

Excerpt

Findings from the primary analysis of the trial were published in 2019.2 At a median follow-up of 22.7 months, both rPFS and OS reached statistical ...

Article found on: www.cancernetwork.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up